---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-24-000127"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:32:48.306545+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolus Q3 revenue $61.1M (+22% YoY); narrows FY2024 guidance to $260-266M

## Summary
- Q3 net revenue $61.1M, up 22% from $50.0M in Q3 2023; year-to-date growth 33%.
- Full-year 2024 revenue guidance narrowed to $260-266M (29-32% YoY growth).
- Received EU approval for Estyme HA gels; U.S. PMA for Evolysse under FDA review, launch expected by Sep 2025.
- Evolus Rewards loyalty program exceeded 1M enrolled consumers and 2M total redemptions.
- Reaffirms positive non-GAAP operating income target for Q4 2024 and full year 2025.

## SEC filing metadata
- accession: 0001570562-24-000127
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056224000127/0001570562-24-000127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056224000127/eols-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-24-000127
- JSON: https://secwatch.observer/filing/0001570562-24-000127.json
- Plain text: https://secwatch.observer/filing/0001570562-24-000127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.